Review: taking Warfarin sodium and Pletal together


Summary

Drug interactions are reported among people who take Warfarin sodium and Pletal together. This review analyzes the effectiveness and drug interactions between Warfarin sodium and Pletal. It is created by eHealthMe based on reports of 639 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Warfarin sodium and Pletal >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Warfarin Sodium

Warfarin sodium has active ingredients of warfarin sodium. It is often used in atrial fibrillation/flutter. (latest outcomes from Warfarin sodium 49,826 users)

Pletal

Pletal has active ingredients of cilostazol. It is often used in cerebral infarction. (latest outcomes from Pletal 5,430 users)

On Aug, 24, 2016

639 people who take Warfarin Sodium, Pletal are studied.


Number of reports submitted per year:

Warfarin sodium and Pletal drug interactions.

Drug effectiveness over time:

Warfarin Sodium:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 0 people)
Pletal:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 50.0% - (1 of 2 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Warfarin Sodium:
  • female: 0.0% - (0 of 1 people)
  • male: 100.0% - (2 of 2 people)
Pletal:
  • female: 0.0% - (0 of 1 people)
  • male: 100.0% - (1 of 1 people)

Drug effectiveness by age:

Warfarin Sodium:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 100.0% - (2 of 2 people)
  • 60+: 0.0% - (0 of 1 people)
Pletal:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • atrial fibrillation
  • cerebral infarction
  • sudden cardiac death
  • abdominal pain
  • dehydration
  • international normalised ratio increased
  • blood creatinine increased
  • blood urea increased
  • renal failure acute
  • renal impairment
1 - 6 months:
  • thrombosis
  • disseminated intravascular coagulation
  • renal failure acute
  • haematuria
  • haemolytic anaemia
  • platelet count decreased
  • thrombotic microangiopathy
  • cerebral infarction
  • chest pain
  • neutropenia
6 - 12 months:
  • disseminated intravascular coagulation
  • haematuria
  • haemolytic anaemia
  • platelet count decreased
  • renal failure acute
  • thrombosis
  • thrombotic microangiopathy
  • blood creatinine increased
  • dyspnoea
  • fall
1 - 2 years:
  • headache
  • renal impairment
  • urinary tract infection
  • abdominal pain
  • arthralgia
  • asthenia
  • blood creatinine increased
  • blood urea increased
  • chills
  • cholangitis
2 - 5 years:
  • anaemia
  • interstitial lung disease
  • bone marrow failure
  • gaze palsy
  • rash
  • electrocardiogram qt prolonged
  • torsade de pointes
  • ventricular tachycardia
  • atrioventricular block complete
  • electrocardiogram qt corrected interval prolonged
5 - 10 years:
  • disseminated intravascular coagulation
  • hepatic function abnormal
  • rhabdomyolysis
  • pneumonia
  • pyrexia
  • sudden death
  • anaemia
  • anal haemorrhage
  • atrial fibrillation
  • cerebrovascular disorder
not specified:
  • atrial fibrillation
  • pain
  • anxiety
  • dyspnoea
  • arthralgia
  • myocardial infarction
  • cardiac failure congestive
  • oedema peripheral
  • mitral valve incompetence
  • injury

Most common drug interactions by gender *:

female:
  • atrial fibrillation
  • pain
  • anxiety
  • coronary artery disease
  • pain in extremity
  • haemoglobin decreased
  • hypertension
  • anaemia
  • hyperlipidaemia
  • arthralgia
male:
  • atrial fibrillation
  • dyspnoea
  • pneumonia
  • cardiac failure congestive
  • headache
  • myocardial infarction
  • pain
  • arthralgia
  • oedema peripheral
  • dehydration

Most common drug interactions by age *:

0-1:
  • disseminated intravascular coagulation
  • hepatic function abnormal
  • rhabdomyolysis
  • pneumonia
  • pyrexia
  • fall
  • international normalised ratio increased
  • pelvic fracture
20-29:
  • back pain
  • pneumonia
  • rhinitis allergic
  • acute tonsillitis
  • dental caries
  • dermatitis allergic
  • eczema
  • enterocolitis
  • gastroenteritis
  • gingival bleeding
30-39:
  • white blood cell count decreased
  • acute tonsillitis
  • constipation
  • cough
  • dental caries
  • dermatitis allergic
  • diarrhoea
  • dizziness
  • eczema
  • enterocolitis
40-49:
  • lymphoedema
  • venous thrombosis limb
  • pleural effusion
  • pulmonary embolism
  • thrombosis
  • cranial nerve palsies multiple
  • disseminated intravascular coagulation
  • haematuria
  • haemolytic anaemia
  • mononeuropathy multiplex
50-59:
  • diarrhoea
  • renal failure
  • nausea
  • pyrexia
  • disseminated intravascular coagulation
  • haemorrhage
  • metabolic acidosis
  • multi-organ failure
  • renal haemorrhage
  • dyspnoea
60+:
  • atrial fibrillation
  • asthenia
  • anaemia
  • coronary artery disease
  • anxiety
  • pain
  • arthralgia
  • dyspnoea
  • international normalised ratio increased
  • hypertension

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Warfarin sodium and Pletal?

Can you answer these questions?

More questions for: Warfarin sodium, Pletal

You may be interested in these reviews

More reviews for: Warfarin sodium, Pletal

On eHealthMe, Warfarin sodium (warfarin sodium) is often used to treat atrial fibrillation/flutter. Pletal (cilostazol) is often used to treat cerebral infarction. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.